All In Biotech

Drug Trial Radar · NCT05952557

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 5,511 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,511

Actual

Start

Oct 5, 2023

Primary completion

Mar 4, 2030

Study completion May 6, 2037

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Austrian Breast & Colorectal Cancer Study Group
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Conditions

  • Breast Cancer, Early Breast Cancer

Interventions

  • CamizestrantDrug

    Camizestrant. Experimental. Administered orally

  • TamoxifenDrug

    Tamoxifen. Comparator. Administered orally

  • AnastrozoleDrug

    Anastrozole. Comparator. Administered orally

  • LetrozoleDrug

    Letrozole. Comparator. Administered orally

  • ExemestaneDrug

    Exemestane. Comparator. Administered orally

  • AbemaciclibDrug

    Abemaciclib adjuvant treatment Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive breast cancer-free survival (IBCFS)Time frame: Up to 14 years

Locations

661 sites in 44 countries. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Fayetteville, Arkansas

  • Research Site

    Duarte, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Irvine, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Walnut Creek, California

  • Research Site

    West Hollywood, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Clearwater, Florida

  • Research Site

    Fort Myers, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Marietta, Georgia

  • Research Site

    Thomasville, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Elmhurst, Illinois

  • Research Site

    Naperville, Illinois

  • Research Site

    Urbana, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Scarborough, Maine

  • Research Site

    Annapolis, Maryland

Showing 40 of 661 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.